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ABSTRACT
Anti-NMDA receptor encephalitis (ANMDARE) is a relatively newly discovered autoimmune and inflammatory 
disorder affecting the limbic system. It has a clinical course that includes prodromal, psychiatric, unresponsive, 
and hyperkinetic stages. These stages are often confused with mental health issues in the medical literature, 
but they also share symptoms of various drug intoxication and withdrawal states. Implicit bias in physicians 
regarding substance use disorder and patient demographics can impair delivery of care and outcomes in 
patients with ANMDARE, especially in a setting with a high prevalence of recreational drug use. When clinical 
presentation aligns, this diagnosis should be investigated as soon as possible, even in the case of atypical 
presentations or in those with past or current substance use disorder. Early identification and treatment are 
essential to good outcomes and minimal sequalae at two years. Therefore, it is essential to consider AN-
MDARE with the symptom profile regardless of patient age, sex, race, or clinical disorder. Below, the difficulty 
in diagnosing ANMDARE is detailed in a 32-year-old white male with a history of methamphetamine, opioid, 
benzodiazepine, and marijuana use.
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Anti-NMDA receptor encephalitis (ANMDARE) is a 
recently discovered autoimmune and inflammato-
ry neurologic disorder first identified in a cohort of 
four women with ovarian teratomas,1,2 but officially 
described two years later by Dalmau in 2007.3,4 Pre-
dominantly seen in non-Caucasian1,3,5 females (4:1)1,3-8 
in their third decade of life,3 it can also 
be seen in other mammal species.9 
Presentation normally ranges between 
19 to 45 years of age4 with a median of 
21 years.10 ANMDARE has been highly 
associated with underlying tumors, 
especially those containing neural 
tissue,1 98% of these being ovarian 
teratomas.2-6,11-14 Testicular teratomas 
and small cell lung cancer can be seen, 
especially in males.2,3
ANMDARE often presents with four 
stages of characteristic symptoms 
(Table 1). A prodromal stage is first 
to present with constitutional symp-
toms.1,3,5,7,9,11,12,15 This period is often 
missed, and clinical presentation usually occurs with 
the hallmark psychiatric stage.1,2,4-8,10,11,13-16  The third 
stage is an unresponsive stage with catatonia, athe-
tosis, and orofacial dyskinesia.1,3,5,8,9,11-13  Seizures can 
occur,2-6,8-16 but tend to be partial rather than gener-
alized1 and rarely advance to status epilepticus.1,2,5 
Finally, the hyperkinetic stage occurs with autonomic 
instability, arrhythmias, hypotension or hypertension, 
central hypoventilation, hyperthermia, and urinary 
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TABLE 1. Four stages of characteristic 
symptons of ANMDARE. 
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incontinence.1-5,7-14,16   
Due to the psychiatric symptoms, ANMDARE is often 
confused with mental health conditions in the cur-
rent literature. Despite the unresponsiveness, sei-
zures, and autonomic dysfunction, little is mentioned 
about confusion with substance use disorders. With 
the potential for implicit bias of healthcare workers 
towards patients with substance use disorders, pa-
tient care can be deleteriously affected.17 Below, the 
effect of biases is explored in this case of ANMDARE 
in the setting of an area with a high prevalence of 
recreational substance use. 
CASE PRESENTATION
A 32-year-old Caucasian male with a past medical 
history of substance use disorder, anxiety, and bac-
terial meningitis presented to an outside hospital for 
seizure-like activity. Urine drug screen was positive 
for methadone, marijuana, and benzodiazepines. The 
patient declined further neurologic workup due to 
fear of needles and confined spaces and was treated 
with levetiracetam (Keppra) empirically.  
After discharge, the patient’s family noted him 
making random odd comments. He also experienced 
auditory hallucination followed by several minutes 
of tonic-clonic seizure activity, despite compliance 
with levetiracetam. This was followed by a post-ictal 
state. In the emergency department, the patient was 
alert, oriented to person, and able to follow simple 
commands. Neurologic and musculoskeletal exam-
ination were unremarkable. Laboratory assessment 
revealed a leukocytosis (13 k/mL), low thyroid stimu-
lation hormone (0.323 mIU/L) with normal free t3/t4 
(2.86 pg/dL and 1.01 µg/dL), normal creatine phos-
phokinase (144 U/L), normal metabolic profile, and a 
drug screen positive for methadone and marijuana. 
Neurology placed him on long-term video monitor-
TABLE 2. Different Diagnosis for anti-NMDA receptor encephalitis. (GABA = Gamma Aminobutyric 
Acid, AMPA = alpha-Amino-3-Hydroxy-5-Methyl-Isoxazoleproionic Acid, LDI1 = Leucine-Rich Gli-
oma-Inactivated 1, PANDAS = Pediatric Autoimmune Neuropsychiatric Disorders Associated with 
Streptococcal Infections)1, 2, 5
Differential Diagnosis
Central Nervous System
Demyelinating Disorders Acute Disseminated Encephalomyelitis, Neuromyelitis Optica
Encephalitis Autoimmune GABA, AMPA, LGI1 receptors
Autoimmune Synaptic Receptor
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ing (LTVM) and changed his levetiracetam to valproic 
acid (Depakene). Workup for infectious etiologies was 
initiated, and he was monitored for benzodiazepine 
withdrawal.
During hospital day 2, the patient was described as 
“looking scared... holding stomach... and…spitting” 
on LTVM. Electroencephalogram during the event 
showed left temporal sharply contoured theta epi-
leptic activity. His valproic acid was increased, and 
he underwent MRI, which showed patchy meningeal 
signal enhancement in cerebral cortices concerning 
for chronic meningitis. Lumbar puncture (LP) was 
performed showing pattern concerning for viral 
meningitis. He was started on Acyclovir while the PCR 
was pending.
The patient continued to have anxiety, paranoia, 
and fluctuating mental status. His symptoms were 
magnified during periods of invasive testing, which 
required general anesthesia to complete. Suspecting 
polysubstance dependence versus delirium, psychia-
try started him on ziprasidone (Geodon). On hospital 
day 10, he experienced an auditory hallucination 
preceding a seizure despite adequate valproic acid 
levels. Infectious workup, including herpes PCR, re-
turned negative, as did aerobic, anerobic, and fungal 
cerebrospinal fluid cultures. Carbamazepine was 
added. A repeat LP was performed for auto-immune 
encephalitis, and empiric steroids were initiated. 
TABLE 3. Comparison of stages of anti-NMDA receptor encephalitis with symptoms of different 
substance use and withdrawal disorders.
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On hospital day 23, anti-NMDA-receptor antibod-
ies were reported positive. IVIG was started as his 
steroids were tapered. Paraneoplastic workup was 
performed, which found no malignancy; however, a 
prosthetic left testicle was discovered, the etiology 
of which the patient could not recall. He suffered no 
further seizures, though he still dealt with significant 
anxiety. He was discharged home on hospital day 28 
with family care. 
DISCUSSION
Encephalitis is an inflammatory disorder of the 
brain11,13 that develops rapidly17 and has a wide 
differential (Table 2).  It occurs in 5-10 per 100,000 
people yearly, but this is likely an underestimation.3 
Encephalitis in the limbic system, which includes 
the medial temporal lobes, amygdala, and cingulate 
gyrus,11 affects the function of the brain regarding 
emotions, anesthesia induced amnesia, aversive 
memories, and addictive behavior.4  ANMDARE is 
the most common autonomic limbic encephali-
tis.12 It constitutes up to 40% of viral negative1 and 
idiopathic encephalitis2 and also 1% of patients with 
encephalitis in the intensive care unit.1  NMDA recep-
tors are located in the forebrain and hippocampus,2,3 
as well as the basal ganglia, spinal cord, and cere-
bellum.5 The receptors are tetramers of glutamine 
subunits (2 GluN1 and 2 GluN2/3)1,3,4,7,13 that work as 
ligand-gated channels. Through dopamine, sero-
tonin, and glutamate, they play a role in Schizophre-
nia,2,4 Parkinson’s disease,2,8 Alzheimer’s disease,2,8 
and synaptic plasticity,1 the latter of which is import-
ant for memory, learning, and cognition.1,8  Expressed 
symptoms depend upon affected receptor location.5 
While the exact cause has not been clarified,6 patho-
physiology follows autoimmune principles as IgG 
autoantibodies target the extracellular N-terminal of 
the GluN1 subunit.1,8 Crosslinking causes reversible7,8 
internalization of both excitatory and inhibitory 
receptors,7 which can be seen two hours after in vitro 
exposure.1-5,7 Long-term exposure causes excitability 
of receptors upon withdrawal.18 The high prevalence 
of comorbid tumors, especially those with neurogen-
ic components like ovarian teratomas,2-6,11-14 suggest 
a paraneoplastic etiology2 and might supply the 
antigenic source for this disease.
The workup for autoimmune encephalitis, consisting 
of antibody testing, inflammatory markers, imaging 
changes, and immunotherapy response, is straight-
forward.13 ANMDARE can be diagnosed with the triad 
of 1) rapid onset of classic symptoms, 2) typical elec-
troencephalogram (EEG) findings of diffuse or local 
slowing2,3,5,11,16 and extreme delta brush,3,5,11,16 and 3) a 
reasonable exclusion of alternative causes.13  
However, cerebrospinal fluid (CSF) and serum IgG 
anti-GLuN1 antibodies coupled with the exclusion 
of other diagnoses is considered reasonable certain-
ty.8,13 What is difficult, especially in an environment of 
significant substance use, is even considering the di-
agnosis in the first place. The onset of ANMDARE typ-
ically presents with psychiatric symptoms, confusing 
it with acute intoxication or recreational substance 
withdrawal. This requires sequential elimination of 
alternate options from the differential (Table 2). Psy-
chiatric diagnoses can be ruled out by the patient’s 
progression to the unresponsive and/or hyperkinetic 
stages of ANMDARE.  Differentiating it from sub-
stance use disorder is more complex because of the 
wide range of overlapping symptoms (Table 3).  
Serologic testing lacks the specificity of CSF test-
ing.3,11,13,15 While IgG antibodies of the GluN1 subunit 
are useful, there is unclear significance for IgA and 
IgM,7,13 as well as autoantibodies for GluN2/3.2,7,12,13 
CSF will usually show lymphocytic pleocytosis and 
oligoclonal bands.1-3,5,11,13,16 EEG is abnormal in 90% 
of ANMDARE cases,1,3,5,11 making it a useful tool to 
differentiate it from substance use disorder.12 It most 
frequently shows an extreme delta brush pattern or 
synchronized delta wave (1-3Hz) superimposed on 
fast beta activity (20-30Hz)3,5,11,16 that does not 
vary with the circadian rhythm.16 Imaging is largely 
unhelpful, as CT is usually normal and MRI is normal 
up to 70% of the time. When it is positive, findings 
tend to be transient and non-specific,1,2,3,5 with 
increased signal on T2-weighted or fluid attenuat-
ed inversion recovery in hippocampus, cerebellum, 
frontobasal or insular cortex, basal ganglia, brain 
stem, and spinal cord.1 Meningeal enhancement,1,10,11 
frontotemporal atrophy,3 and periventricular white 
matter demyelination1,3,13 can also be observed. PET 
scans can reveal occipital lobe hypometabolism.3 
Locating an associated tumor with testicular or pelvic 
ultrasound may also be helpful in diagnosis.1
As with other autoimmune pathologies, first line 
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treatment of ANMDARE includes decreasing autoan-
tibodies through immunotherapies of steroids, IVIG, 
and plasmapheresis.1-8,11,14,15 Resection of a tumor, if 
one is identified, improves success of treatment to 
80% in combination with first-line immunotherapies. 
If those fail, second line treatment is rituximab or cy-
clophosphamide,1-3,5,6,10,11,14,15 which decreases auto-
antibody formation by depleting memory B cells, but 
is limited due potential side effects.8 Multiple forms 
of treatment have proven effective.6,15 Still, long-term 
treatment, prolonged hospitalizations, and rehabili-
tation are common.1 High levels of recovery from AN-
MDARE, as defined by Modified Rankin Scores, occur 
in approximately 80% of patients within 2 years of 
disease onset.3,10,11,15 Predictors of good outcomes 
include lower severity of symptoms, lower levels of 
antibody titers, and early detection of the disorder, 
thus leading to early immunotherapy and/or tumor 
resection.1,3,5 In fact, not starting treatment within 4 
weeks of onset strongly predicts a poor outcome at 
1 year.14 
Implicit bias in healthcare professionals presents 
a potential barrier to early detection of, and thus 
better recovery from, ANMDARE. Central Appala-
chia shares the nation’s prevalence of substance use 
disorders, where up to 50% of urban emergency 
departments and up to 40% of inpatient admissions 
involve alcohol and other substance use disorders.19 
Overall, physicians carry negative attitudes towards 
patients with substance use disorder,17 and these 
attitudes deteriorate throughout training.19  Patients 
are labelled as “difficult,” as they are perceived to 
repetitively over-utilize healthcare and monopolize 
resources.19 These stigmatizing attitudes can affect 
healthcare delivery through avoidant behaviors, 
poor communication, and misattributing physical 
symptoms.17 Medical errors can occur from any of the 
32 different identified cognitive biases, but diagnos-
tic inaccuracies predominately are associated with 
overconfidence, anchoring effect, information bias, 
and availability bias.20  
In this case, the patient’s gender decreased the 
likelihood of ANMDARE. Furthermore, anchoring on 
his substance use disorder delayed diagnosis and 
treatment. Alternative diagnoses, including AN-
MDARE, should be considered when symptoms per-
sist beyond the expected course of intoxication or 
withdrawal, or if seizures persist despite therapeutic 
levels of anticonvulsants. Ongoing use of recreational 
substances can prolong these times, but this can be 
reassessed with repeated drug screening.
CONCLUSION
ANMDARE is a complex medical condition that can 
easily be mistaken for psychiatric and substance use 
disorders. Physicians should consider all possible dif-
ferential diagnoses, regardless of patient history and 
background, when presented with symptoms that re-
semble ANMDARE in order to get prompt treatment 
and increase the likelihood of full recovery.
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